PHASE III RANDOMIZED STUDY OF INTRAVENOUS CISPLATIN AND CYCLOPHOSPHAMIDE

静脉注射顺铂和环磷酰胺的 III 期随机研究

• 批准号: 3740313
• 负责人: HARRISON G BALL
• 金额: --
• 依托单位: TUFTS MEDICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3740313
• 关键词: cis platinum compound; clinical trials; combination chemotherapy; cyclophosphamide; drug administration routes; drug adverse effect; female; human subject; human therapy evaluation; injection /infusion; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; ovary neoplasms; paclitaxel; pathologic process

The purpose of this study is to compare recurrence-free interval, complete pathologic response, and survival between the standard regimen: intravenous cisplatin, cyclophosphamide and the two experimental regimens: 1) intravenous cisplatin/taxol and 2) intravenous carboplatin followed by intravenous taxol and intraperitoneal cisplatin in patients with optimal stage III epithelial ovarian carcinoma.

本研究的目的是比较无复发间期， 标准方案之间的完全病理学缓解和生存率： 顺铂、环磷酰胺和两种实验性 方案：1）静脉内顺铂/紫杉醇和2）静脉内卡铂 然后静脉注射紫杉醇 和腹膜内顺铂 最佳III期上皮性卵巢癌患者。